SCHOTT Pharma Begins Fiscal Year 2025 with Promising Results

SCHOTT Pharma reported a strong start to fiscal year 2025 with revenues reaching EUR 230 million, a slight 1% decline year-on-year. At constant currencies, revenues increased by 4%, indicating a robust performance. The EBITDA margin stood at 25.1%, improving to 26.3% at constant currencies. High-value solutions (HVS) contributed 55% to the revenue, underlining the company's strategic focus.

CEO Andreas Reisse highlighted significant growth in biologics and subcutaneous administration. Meanwhile, CFO Dr. Almuth Steinkühler emphasized the importance of increased capacities in glass syringes and sterile cartridges for the second half of 2025.

The DCS segment witnessed strong demand for HVS, with revenues reaching EUR 129 million. Conversely, the DDS segment saw stable revenues despite reduced EBITDA due to scale-up costs. SCHOTT Pharma remains optimistic about achieving its fiscal expectations, driven by ongoing expansion projects and cost-efficiency measures.